RAVE
Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis
Patient / Population Intervention / Exposition Comparaison Critère de jugement
In 197 patients with severe ANCA-associated vasculitis, rituximab was non-inferior for inducing remission compared with cyclophosphamide.
N
197
Schéma
Double-blind, double-dummy RCT
Critère
Complete remission without steroids at month 6
Pertinence
1
RésultatRituximab 64% vs cyclophosphamide 53% (non-inferior); superior in the relapsing subgroup.
Stone JH, et al. N Engl J Med. 2010;363(3):221-232. 10.1056/NEJMoa0909905
Discussion et critique
Established rituximab as standard induction in ANCA vasculitis, sparing cyclophosphamide exposure.